Hikma Delivers On Authorized Xyrem In US
Also Strikes Deal With Junshi For Toripalimab In MENA Region
Hikma has begun 2023 with the long-awaited launch of a US authorized generic version of Xyrem (sodium oxybate). Meanwhile, the company has also struck a deal with Junshi Biosciences for toripalimab in the MENA region.
You may also be interested in...
Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.
Hikma has provided a trading update in which it revised its expectations upwards for both its generic and branded business, while anticipating that its injectables unit will perform at the lower end of its current expectations.
Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.